November 28, 2016 - By Linda Rogers · 0 Comments
The stock of Cleveland Biolabs Incorporated (NASDAQ:CBLI) registered a decrease of 0.96% in short interest. CBLI’s total short interest was 165,800 shares in November as published by FINRA. Its down 0.96% from 167,400 shares, reported previously. With 31,900 shares average volume, it will take short sellers 5 days to cover their CBLI’s short positions. The short interest to Cleveland Biolabs Incorporated’s float is 6.78%. About 21,929 shares traded hands. Cleveland BioLabs, Inc. (NASDAQ:CBLI) has declined 32.77% since April 25, 2016 and is downtrending. It has underperformed by 38.78% the S&P500.
Cleveland BioLabs, Inc. is a biopharmaceutical company. The company has a market cap of $17.61 million. The Company’s programs are focused developing approaches to activate the immune system and address serious medical needs. It currently has negative earnings. The Company’s platform of Toll-like immune receptor activators has applications in mitigation of radiation injury and immuno-oncology.
Insitutional Activity: The institutional sentiment increased to 1.25 in Q2 2016. Its up 0.82, from 0.43 in 2016Q1. The ratio improved, as 5 funds sold all Cleveland BioLabs, Inc. shares owned while 2 reduced positions. 0 funds bought stakes while 3 increased positions. They now own 406,408 shares or 4.11% less from 423,822 shares in 2016Q1.
Blackrock Advsr Limited Liability Company has 0% invested in the company for 2,800 shares. Us National Bank De reported 100 shares or 0% of all its holdings. Vanguard Grp last reported 0% of its portfolio in the stock. Winfield Assoc last reported 0% of its portfolio in the stock. Geode Management Llc has invested 0% of its portfolio in Cleveland BioLabs, Inc. (NASDAQ:CBLI). Pine River Capital Management Lp holds 150,000 shares or 0% of its portfolio. Deutsche Fincl Bank Ag reported 87 shares or 0% of all its holdings. Group Inc One Trading L P accumulated 0% or 68 shares. Blackrock Fund Advsrs holds 0% or 684 shares in its portfolio. Morgan Stanley, a New York-based fund reported 1,255 shares. The North Carolina-based Retail Bank Of America Corporation De has invested 0% in Cleveland BioLabs, Inc. (NASDAQ:CBLI). Bancshares Of Montreal Can holds 0% of its portfolio in Cleveland BioLabs, Inc. (NASDAQ:CBLI) for 31 shares. Manufacturers Life Insur The has invested 0% of its portfolio in Cleveland BioLabs, Inc. (NASDAQ:CBLI). Cowen Gru last reported 109,375 shares in the company. Ladenburg Thalmann Financial Services last reported 36,643 shares in the company.
Cleveland BioLabs, Inc. (CBLI), incorporated on June 5, 2003, is a biopharmaceutical company. The Company’s programs are focused developing approaches to activate the immune system and address serious medical needs. The Company’s platform of Toll-like immune receptor activators has applications in mitigation of radiation injury and immuno-oncology. CBLI’s advanced product candidate is entolimod, an immuno-stimulatory agent, which the Company is developing as a radiation countermeasure and an immunotherapy for oncology and other indications. It also has an additional clinical-stage program and multiple projects in different stages of preclinical drug development. The Company’s products include Entolimod, CBLB612 and Mobilan.
More notable recent Cleveland BioLabs, Inc. (NASDAQ:CBLI) news were published by: Quotes.Wsj.com which released: “News Cleveland BioLabs Inc.CBLI” on February 11, 2011, also Marketwatch.com with their article: “Cleveland BioLabs Reports Second Quarter 2016 Financial Results and …” published on August 15, 2016, Thestreet.com published: “Cleveland BioLabs (CBLI) Stock Spikes on $25 Million Equity Financing Agreement” on June 25, 2015. More interesting news about Cleveland BioLabs, Inc. (NASDAQ:CBLI) were released by: Medgadget.com and their article: “Cleveland BioLabs, Inc. Pipeline Reviews and Clinical Trail Assessment 2016 …” published on September 13, 2016 as well as Streetinsider.com‘s news article titled: “Cleveland Biolabs (CBLI) Announces $1.1M JWMRP Contract Modification with U.S. DoD” with publication date: October 11, 2016.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.
By Linda Rogers